Navigation Links
Experimental drug shows promise against brain, prostate cancers
Date:1/3/2010

DALLAS Jan. 4, 2010 An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

The drug's actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer's growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The glioblastoma study appears in the January issue of Clinical Cancer Research. The prostate cancer study is available online in the International Journal of Cancer.

In the glioblastoma study, performed in mice, the drug also crossed from the bloodstream into the brain, which is especially important because many drugs are not able to cross the blood-brain barrier.

"Because it attacks a mechanism that's active in most cancers, it might prove to be widely useful, especially when combined with other therapies," said Dr. Shay.

Dr. Shay and his colleagues study telomeres, bits of DNA that help control how many times a cell divides. Telomeres are protective "caps" of DNA on the ends of chromosomes, the structures that contain the body's genes. As long as telomeres are longer than a certain minimum length, a cell can keep dividing. But telomeres shorten with each cell division, so a cell stops dividing once the telomeres are whittled down to that minimum.

In cancer cells, however, an enzyme called telomerase keeps rebuilding the telomeres, so the cell never receives the cue to stop dividing. In essence, they become immortal, dividing endlessly.

The drug used in these studies (imetelstat or GRN163L) blocks telomerase. It is already in clinical trials as a potential treatment for breast an
'/>"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Experimental Biology 2008 meets in San Diego April 5-9
2. Translational research patented first experimental treatment against idiopathic pulmonary fibrosis
3. Experimental Biology and Medicine announces expansion into Asia, opens new office
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. French scientist wins the Journal of Experimental Biology Outstanding Paper Prize
6. Survival in a Changing World: The Journal of Experimental Biology 2009 symposium
7. 40 minority scientists receive travel fellowships to Experimental Biology 2009 in New Orleans
8. Experimental treatment halts hypoxic-ischemic brain injury in newborns
9. Experimental treatments restore partial vision to blind people
10. French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009
11. Research shows skeleton to be endocrine organ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... the "Fingerprint Sensors Market in Smart Mobile Devices ... report believes that 2014 was a watershed year for ... introduction of ,Apple Pay,. Apple gave fingerprint sensors a ... payment service. Fingerprint sensors are a must-have feature in ...
(Date:5/10/2015)... 2015 Fingerprint Cards (FPC) has received ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... smartphone manufacturers in China . The order ... guidance of + 1 000 MSEK for 2015.   ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... breakthrough in sensing at Rice University could make finding signs ... light. The technique reported in the Journal ... better medications to treat the devastating disease. The lab ... naturally attach themselves to a collection of beta amyloid proteins ...
... including stomach, liver and colon, are far more common in ... in lifestyle, such as diet and smoking, may account for ... rooted in basic biological differences between men and women. ... that treating male mice with estrogen dramatically lowers their rates ...
... COLLEGE PARK, Md. -- A new University of ... the 2009 flu pandemic (H1N1) and a common type of ... flu viruses -- with the potential for creating a new ... but University of Maryland virologist Daniel Perez, who directed the ...
Cached Biology News:Molecules 'light up' Alzheimer's roots 2Molecules 'light up' Alzheimer's roots 3Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3When well-known flu strains 'hook up' dangerous progeny can result 2When well-known flu strains 'hook up' dangerous progeny can result 3
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
(Date:5/20/2015)... May 20, 2015  Select Medical Corporation ("Select") ... Trade Commission granted early termination of the waiting ... of 1976, as amended, applicable to the acquisition ... a joint venture that Select has created with ... As previously announced, MJ Acquisition Corporation has signed ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... VRUS ) management will present at Cowen & ... 2008 at Boston Marriott,Copley Place in Boston, MA. Schaefer ... the company on Tuesday, March 18, 2008,from 3:55 PM ... access a simultaneous webcast of Mr. Price,s overview of ...
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") today ... 31, 2007. All results are in U.S.,dollars and prepared ... ended December 31, 2007, was $20.3 million or,$1.04 per ... $2.38,per basic and diluted share in 2006. The substantial ...
... MannKind,Corporation (Nasdaq: MNKD ) today issued the ... MannKind is absolutely committed to the continued development ... our small,patient-friendly Medtone(R) inhaler to deliver Technosphere(R) Insulin ... more closely matches the pattern,of insulin secretion seen ...
Cached Biology Technology:Pharmasset to Present at Cowen & Company's Health Care Conference on Tuesday, March 18th 2Oncothyreon reports full year and fourth quarter 2007 financial results 2Oncothyreon reports full year and fourth quarter 2007 financial results 3Oncothyreon reports full year and fourth quarter 2007 financial results 4Oncothyreon reports full year and fourth quarter 2007 financial results 5Oncothyreon reports full year and fourth quarter 2007 financial results 6Oncothyreon reports full year and fourth quarter 2007 financial results 7MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6
... results - with a modular approach to ... The ChemStation Plus NDS family provides modular ... and data management, giving you the flexibility ... labs needs now and that can grow ...
... 'Agilents GeneSpring Workgroup solution is ... managing and mining expression data in ... and is deployed in over 40 ... research organizations worldwide. GeneSpring Workgroup streamlines ...
... proteomic scale kinase profiling, quantitative measurement ... discovery research built on the flexible ... platform. These microarrays are available as ... Substrate - Peptide Microarray Service. ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences are ... is (amino to carboxy terminus): S(21) - S - M - ... - E - A - I - D - K - ... This peptide may be used for neutralization and control ...
Biology Products: